Lenalidomide after Stem-Cell Transplantation for Multiple MyelomaPhilip L. McCarthy, Charles Linker, Chen Jiang et al.|New England Journal of Medicine|2012Cited by 1.1k
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic SyndromesBart L. Scott, Mitchell E. Horwitz, Marcelo C. Pasquini et al.|Journal of Clinical Oncology|2017Cited by 664
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual DiseaseChristopher S. Hourigan, Mitchell E. Horwitz, Laura W. Dillon et al.|Journal of Clinical Oncology|2019Cited by 441
Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II TrialPhilippe Armand, Leo I. Gordon, Arnon Nagler et al.|Journal of Clinical Oncology|2013Cited by 439
Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and RecommendationsSergio Giralt, Steven M. Devine, Luciano J. Costa et al.|Biology of Blood and Marrow Transplantation|2013Cited by 402